ES2692396T3 - Inhibidores de la replicación de virus de influenza - Google Patents

Inhibidores de la replicación de virus de influenza Download PDF

Info

Publication number
ES2692396T3
ES2692396T3 ES16181549.3T ES16181549T ES2692396T3 ES 2692396 T3 ES2692396 T3 ES 2692396T3 ES 16181549 T ES16181549 T ES 16181549T ES 2692396 T3 ES2692396 T3 ES 2692396T3
Authority
ES
Spain
Prior art keywords
mhz
nmr
ppm
alkyl
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16181549.3T
Other languages
English (en)
Spanish (es)
Inventor
Paul Charifson
Michael P. Clark
Upul K. Bandarage
Randy S. Bethiel
John J. Court
Hongbo Deng
Ioana Drutu
John P. Duffy
Luc Farmer
Huai Gao
Wenxin Gu
Dylan H. Jacobs
Joseph M. Kennedy
Mark W. Ledeboer
Brian Ledford
Francois Maltais
Emanuele Perola
Tiansheng Wang
M. Woods Wannamaker
Randal Byrn
Yi Zhou
Chao Lin
Min Jiang
Ursula A. Germann
Steven Jones
Francesco G. Salituro
Ann Dak-Yee Kwong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2692396(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2692396T3 publication Critical patent/ES2692396T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES16181549.3T 2009-06-17 2010-06-17 Inhibidores de la replicación de virus de influenza Active ES2692396T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18771309P 2009-06-17 2009-06-17
US187713P 2009-06-17
US28778109P 2009-12-18 2009-12-18
US287781P 2009-12-18

Publications (1)

Publication Number Publication Date
ES2692396T3 true ES2692396T3 (es) 2018-12-03

Family

ID=42537408

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16181549.3T Active ES2692396T3 (es) 2009-06-17 2010-06-17 Inhibidores de la replicación de virus de influenza
ES10726760.1T Active ES2604667T3 (es) 2009-06-17 2010-06-17 Inhibidores de la replicación de virus de influenza

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10726760.1T Active ES2604667T3 (es) 2009-06-17 2010-06-17 Inhibidores de la replicación de virus de influenza

Country Status (37)

Country Link
US (7) US20120171245A1 (enExample)
EP (3) EP2442809B1 (enExample)
JP (6) JP5721706B2 (enExample)
KR (3) KR101903354B1 (enExample)
CN (5) CN102458408B (enExample)
AP (1) AP3631A (enExample)
AR (1) AR077130A1 (enExample)
AU (1) AU2010262905B2 (enExample)
BR (1) BRPI1011993A2 (enExample)
CA (1) CA2764177C (enExample)
CL (1) CL2011003192A1 (enExample)
CO (1) CO6491048A2 (enExample)
CY (2) CY1118246T1 (enExample)
DK (2) DK3141252T3 (enExample)
EA (3) EA030188B1 (enExample)
EC (1) ECSP12011610A (enExample)
ES (2) ES2692396T3 (enExample)
GE (3) GEP20207129B (enExample)
HR (2) HRP20161577T1 (enExample)
HU (1) HUE031048T2 (enExample)
IL (2) IL216980B (enExample)
LT (2) LT3141252T (enExample)
ME (1) ME02558B (enExample)
MX (3) MX2011013475A (enExample)
NZ (2) NZ619259A (enExample)
PE (2) PE20160127A1 (enExample)
PH (1) PH12015501678B1 (enExample)
PL (2) PL2442809T3 (enExample)
PT (2) PT3141252T (enExample)
RS (2) RS57869B1 (enExample)
SG (3) SG176722A1 (enExample)
SI (2) SI3141252T1 (enExample)
TR (1) TR201815272T4 (enExample)
TW (4) TWI483941B (enExample)
UY (1) UY32717A (enExample)
WO (1) WO2010148197A1 (enExample)
ZA (2) ZA201109127B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
TWI483941B (zh) * 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
KR20130128435A (ko) * 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
JP2013545817A (ja) * 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
KR101760164B1 (ko) 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
WO2013006634A2 (en) * 2011-07-05 2013-01-10 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US10323012B2 (en) * 2012-06-05 2019-06-18 Hong Kong Baptist University Miliusanes as antiviral agents
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
UA118094C2 (uk) * 2012-11-21 2018-11-26 Пітісі Терап'Ютикс, Інк. Заміщені зворотні піримідинові інгібітори bmi-1
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
RU2685730C1 (ru) * 2013-11-13 2019-04-23 Вертекс Фармасьютикалз Инкорпорейтед Составы соединений азаиндола
SMT201900450T1 (it) * 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) * 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
HRP20190039T1 (hr) 2014-04-04 2019-03-08 Syros Pharmaceuticals, Inc. Inhibitori ciklin-ovisne kinaze 7 (cdk7)
SG11201700956VA (en) 2014-08-08 2017-03-30 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
ES2860688T3 (es) * 2014-09-08 2021-10-05 Janssen Sciences Ireland Uc Pirrolopirimidinas para uso en la infección por el virus de la gripe
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
KR102542097B1 (ko) * 2015-01-16 2023-06-09 바이엘 크롭사이언스 악티엔게젤샤프트 4-시아노피페리딘 하이드로클로라이드의 제조 방법
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US20180134730A1 (en) * 2015-05-26 2018-05-17 BoroPharm Inc. Improved process for preparing boryl 7-azaindole compounds
AU2016359907B2 (en) * 2015-11-27 2021-04-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
AU2016368317B2 (en) * 2015-12-09 2019-05-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
SI3400225T1 (sl) * 2016-01-07 2022-01-31 Janssen Sciences Ireland Unlimited Company Pentanojske kisline substituirane s pirolo-(2-3,b)pirimidin-piridini za zdravljenje okužb z virusom gripe
MX381314B (es) * 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
CN109071567B (zh) * 2016-05-19 2021-03-23 四川大学 抗流感小分子化合物及其制备方法和用途
US10501444B2 (en) 2016-08-16 2019-12-10 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CA3035680C (en) * 2016-09-05 2023-05-02 Jian Xiong Anti-influenza virus pyrimidine derivatives
EP3538523B1 (en) * 2016-11-08 2021-05-19 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors
AU2017376541B2 (en) * 2016-12-15 2021-08-05 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CA3047404A1 (en) 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018191475A1 (en) 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection
MY199746A (en) * 2017-04-24 2023-11-21 Cocrystal Pharma Inc Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
JP2020530446A (ja) 2017-08-09 2020-10-22 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 化合物、組成物、及び、方法
EP3676297B1 (en) 2017-09-01 2023-05-17 Denali Therapeutics Inc. Compounds, compositions and methods
CN109745309B (zh) * 2017-11-03 2022-01-28 香港浸会大学 作为抗病毒剂的密瘤杀
CN110117285B (zh) * 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
NZ767352A (en) * 2018-03-05 2023-05-26 Guangdong Raynovent Biotech Co Ltd Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN111936497A (zh) * 2018-04-06 2020-11-13 杨森制药公司 制备匹莫迪韦盐酸盐半水合物的结晶形式的等温反应性结晶方法
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
MX2021000917A (es) * 2018-07-27 2021-06-23 Cocrystal Pharma Inc Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe.
CN113164479A (zh) 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
JP2022520236A (ja) 2019-02-13 2022-03-29 デナリ セラピューティクス インコーポレイテッド 化合物、組成物、及び、方法
WO2020181247A1 (en) * 2019-03-06 2020-09-10 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020212399A1 (en) 2019-04-15 2020-10-22 Janssen Pharmaceutica Nv Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound
WO2020256820A1 (en) 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
EP3992192A4 (en) * 2019-07-22 2022-08-17 Guangdong Raynovent Biotech Co., Ltd. DOMINANT SALT FORMS OF PYRIMIDINE DERIVATIVES AND CRYSTAL FORMS THEREOF
US20220396575A1 (en) * 2019-08-30 2022-12-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
RU2726119C1 (ru) * 2019-11-22 2020-07-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые производные полиолов, их применение, фармацевтическая композиция на их основе
TW202202500A (zh) 2020-07-10 2022-01-16 大陸商四川海思科製藥有限公司 Pb2抑制劑及其製備方法和用途
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
IL83821A0 (en) 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EP0763035A4 (en) 1994-06-09 1997-10-01 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
US6187713B1 (en) 1996-10-31 2001-02-13 Corning Incorporated Method of making activated carbon bodies having improved adsorption properties
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
KR20010086163A (ko) 1999-01-07 2001-09-08 이곤 이 버그 우울증 치료용 아릴피페라지닐-사이클로헥실 인돌 유도체
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
JP4911864B2 (ja) 2000-08-14 2012-04-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
JP4129391B2 (ja) 2000-09-06 2008-08-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2002024705A1 (en) 2000-09-22 2002-03-28 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
KR20030062442A (ko) 2000-12-22 2003-07-25 와이어쓰 5-하이드록시트립타민-6-리간드로서의 헤테로사이클인다졸및 아자인다졸 화합물
JP4343534B2 (ja) 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト 3ハイブリッド・アッセイ・システム
DE60201829T2 (de) 2001-03-14 2005-10-27 Wyeth Azaheterocyclylmethylderivative des 2,3-dihydro-1,4-dioxino(2,3-f)chinolin als antidepressivum
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1381600A1 (en) 2001-04-24 2004-01-21 Wyeth, A Corporation of the State of Delaware Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
EP1381612A1 (en) 2001-04-26 2004-01-21 Wyeth Antidepressant aza-heterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
MXPA03009828A (es) 2001-04-26 2005-03-07 Wyeth Corp Sssri) azaheterociclilmetil derivados de 7,8-dihidro-3h-t,9-dioxa-1,3-diazaciclopenta[a]naftaleno como agentes antidepresivos.
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
DE60201590T2 (de) 2001-04-26 2005-02-17 Wyeth Antidepressiv wirksame azaheterocyclymethyl-derivative von oxaheterocycyl-anellierten (1,4)-benzodioxanen
JP2004527563A (ja) 2001-04-26 2004-09-09 ワイス 抗うつ作用を有する、2,3−ジヒドロ−1,4−ジオキシノ[2,3−f]キノキサリンのアザへテロシクリルメチル誘導体
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
WO2002088140A1 (en) 2001-04-30 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
MXPA03010524A (es) 2001-05-17 2005-03-07 Wyeth Corp Proceso para la sintesis de derivados de la 2,3-dihidro-1,4-dioxino-[2,3-f]-quinolina.
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
CN100434079C (zh) 2001-08-14 2008-11-19 富山化学工业株式会社 吡嗪核苷酸/吡嗪核苷类似物及其医药用途
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003091258A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP4414881B2 (ja) 2002-05-31 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾール化合物およびこれを含んでなる医薬組成物
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
ATE339419T1 (de) 2002-08-02 2006-10-15 Vertex Pharma Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CN101200457A (zh) 2003-02-26 2008-06-18 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
WO2004078756A2 (en) 2003-03-06 2004-09-16 Eisai Co., Ltd. Jnk inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
JP2007507529A (ja) 2003-09-30 2007-03-29 サイオス・インコーポレーテツド 複素環式アミドおよびスルホンアミド
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
PT1696920E (pt) 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
KR101298967B1 (ko) * 2004-03-30 2013-09-02 버텍스 파마슈티칼스 인코포레이티드 Jak 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
EP1756108A2 (en) 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
TW200616632A (en) 2004-06-17 2006-06-01 Plexxikon Inc Compounds modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
MX2007001127A (es) 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
JP5030229B2 (ja) 2004-11-04 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ[1,5−a]ピリミジン
AU2005309616A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
MX344036B (es) 2004-11-24 2016-12-02 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
JP4954086B2 (ja) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1h−ピロロ[2,3−b]ピリジン
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
ATE420883T1 (de) 2005-02-03 2009-01-15 Vertex Pharma Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
KR20080016643A (ko) 2005-05-16 2008-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피롤로피리딘 유도체
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
JP2009513571A (ja) 2005-09-30 2009-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なデアザプリン
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
RU2453548C2 (ru) 2006-01-17 2012-06-20 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов янус-киназ
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
JP2009528991A (ja) 2006-02-14 2009-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロ(3,2−c)ピリジン
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
AU2007235487A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
AU2007242594A1 (en) * 2006-04-26 2007-11-01 F. Hoffmann-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
MY145385A (en) 2006-08-08 2012-01-31 Chugai Pharmaceutical Co Ltd Pyrimidine derivative as p13k inhibitor and use thereof
AU2007287428B2 (en) * 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2102210B1 (en) 2006-12-14 2011-02-09 Vertex Pharmceuticals Incorporated Compounds useful as protein kinase inhibitors
AR064675A1 (es) 2006-12-21 2009-04-15 Vertex Pharma Derivados heterociclicos de pirrolo- [2,3-b] piridina, inhibidores de proteinquinasas plk, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos hiperproliferativos
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
NZ579485A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
JP5520057B2 (ja) 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
EP2139892B1 (en) 2007-03-22 2011-09-14 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as plk1 inhibitors
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
US8541437B2 (en) 2007-04-05 2013-09-24 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for the production and use thereof
MX2010001677A (es) 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
PL2205603T3 (pl) 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
WO2009046983A1 (en) 2007-10-09 2009-04-16 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
ES2389992T3 (es) 2007-11-02 2012-11-05 Vertex Pharmaceuticals Incorporated Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta
EA022912B1 (ru) 2007-11-05 2016-03-31 Новартис Аг Производные 4-бензиламино-1-карбоксиацилпиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
CA2713710A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
US20110033473A1 (en) 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
CN102076690A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
AU2009271663B2 (en) 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2321318A1 (en) 2008-07-23 2011-05-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
AU2010245914A1 (en) 2009-05-06 2011-12-15 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
TWI483941B (zh) * 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CA2795748C (en) 2010-04-07 2020-12-08 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MX2012011941A (es) 2010-04-14 2013-08-27 Array Biopharma Inc Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas.
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
KR20130128435A (ko) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
JP2013545817A (ja) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
WO2013006634A2 (en) 2011-07-05 2013-01-10 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013070606A1 (en) 2011-11-07 2013-05-16 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
KR20160045070A (ko) 2013-08-22 2016-04-26 버텍스 파마슈티칼스 인코포레이티드 동위원소 풍부 아자인돌
PE20160661A1 (es) 2013-09-12 2016-08-05 Alios Biopharma Inc Compuesto de azapiridona y sus usos de los mismos
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
RU2685730C1 (ru) 2013-11-13 2019-04-23 Вертекс Фармасьютикалз Инкорпорейтед Составы соединений азаиндола
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
SG11201700956VA (en) 2014-08-08 2017-03-30 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
ES2860688T3 (es) 2014-09-08 2021-10-05 Janssen Sciences Ireland Uc Pirrolopirimidinas para uso en la infección por el virus de la gripe
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
AU2016359907B2 (en) 2015-11-27 2021-04-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
SI3400225T1 (sl) 2016-01-07 2022-01-31 Janssen Sciences Ireland Unlimited Company Pentanojske kisline substituirane s pirolo-(2-3,b)pirimidin-piridini za zdravljenje okužb z virusom gripe
MX381314B (es) 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
WO2018191475A1 (en) 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection

Also Published As

Publication number Publication date
US20170100400A1 (en) 2017-04-13
US9518056B2 (en) 2016-12-13
NZ619259A (en) 2015-07-31
SI2442809T1 (sl) 2017-01-31
PE20160127A1 (es) 2016-02-24
EA037529B1 (ru) 2021-04-08
WO2010148197A1 (en) 2010-12-23
PE20120508A1 (es) 2012-05-09
EA201500266A1 (ru) 2015-10-30
CN102458408A (zh) 2012-05-16
US20120171245A1 (en) 2012-07-05
CN104151312B (zh) 2016-06-15
EP2442809A1 (en) 2012-04-25
LT2442809T (lt) 2016-12-12
JP2020011990A (ja) 2020-01-23
AU2010262905B2 (en) 2015-04-16
PL2442809T3 (pl) 2017-02-28
JP2015034177A (ja) 2015-02-19
JP2015038146A (ja) 2015-02-26
PL3141252T3 (pl) 2019-01-31
JP2012530713A (ja) 2012-12-06
CN104151312A (zh) 2014-11-19
US10874673B2 (en) 2020-12-29
ME02558B (me) 2017-02-20
AU2010262905A1 (en) 2012-01-12
CN104922128B (zh) 2019-12-20
US9808459B2 (en) 2017-11-07
KR101702609B1 (ko) 2017-02-03
MX375432B (es) 2025-03-06
KR20120097471A (ko) 2012-09-04
CY1118246T1 (el) 2017-06-28
TW201925196A (zh) 2019-07-01
LT3141252T (lt) 2018-11-12
HK1215530A1 (zh) 2016-09-02
PT3141252T (pt) 2018-11-14
GEP20156325B (en) 2015-07-10
JP2016204390A (ja) 2016-12-08
SI3141252T1 (sl) 2018-12-31
AP3631A (en) 2016-03-08
BRPI1011993A2 (pt) 2021-07-06
EP2442809B1 (en) 2016-08-31
HK1169326A1 (en) 2013-01-25
JP6348939B2 (ja) 2018-06-27
RS55341B1 (sr) 2017-03-31
CN104940202A (zh) 2015-09-30
IL262734B (en) 2020-11-30
CN104940202B (zh) 2018-10-16
KR20170015551A (ko) 2017-02-08
US8829007B2 (en) 2014-09-09
KR101903354B1 (ko) 2018-10-04
EP3141252B8 (en) 2019-03-13
EA025276B1 (ru) 2016-12-30
EP3427738B1 (en) 2021-12-01
ECSP12011610A (es) 2012-02-29
NZ597059A (en) 2014-01-31
TWI483941B (zh) 2015-05-11
JP5721706B2 (ja) 2015-05-20
SG10201405827PA (en) 2014-11-27
US20180078553A1 (en) 2018-03-22
TW201520211A (zh) 2015-06-01
TW201103935A (en) 2011-02-01
US20140142119A1 (en) 2014-05-22
ES2604667T3 (es) 2017-03-08
MX348066B (es) 2017-05-26
AP2012006067A0 (en) 2012-02-29
EA201270032A1 (ru) 2012-07-30
HK1204322A1 (en) 2015-11-13
TWI639596B (zh) 2018-11-01
IL262734A (en) 2018-12-31
MX2011013475A (es) 2012-03-14
US9345708B2 (en) 2016-05-24
TW201728584A (zh) 2017-08-16
KR102050712B1 (ko) 2019-12-02
CN104922128A (zh) 2015-09-23
EA030188B1 (ru) 2018-07-31
CO6491048A2 (es) 2012-07-31
HUE031048T2 (en) 2017-06-28
TWI574963B (zh) 2017-03-21
US20190151314A1 (en) 2019-05-23
DK2442809T3 (en) 2016-12-19
CA2764177A1 (en) 2010-12-23
GEP20227397B (en) 2022-07-25
IL216980A0 (en) 2012-02-29
PH12015501678B1 (en) 2022-07-06
PT2442809T (pt) 2016-12-06
EP3141252B1 (en) 2018-07-25
EP3427738A1 (en) 2019-01-16
ZA201109127B (en) 2015-07-29
AR077130A1 (es) 2011-08-03
CA2764177C (en) 2018-06-05
US10039762B2 (en) 2018-08-07
KR20180108856A (ko) 2018-10-04
PH12015501678A1 (en) 2020-06-22
HRP20161577T1 (hr) 2017-01-27
CL2011003192A1 (es) 2013-01-04
JP6030619B2 (ja) 2016-11-24
CY1120778T1 (el) 2019-12-11
SG10201405826RA (en) 2014-12-30
ZA201500820B (en) 2016-05-25
JP2018002747A (ja) 2018-01-11
RS57869B1 (sr) 2018-12-31
IL216980B (en) 2018-11-29
HK1215675A1 (zh) 2016-09-09
EA201500871A1 (ru) 2016-11-30
UY32717A (es) 2011-01-31
SG176722A1 (en) 2012-01-30
US20160152614A1 (en) 2016-06-02
TWI666209B (zh) 2019-07-21
US20140296201A1 (en) 2014-10-02
DK3141252T3 (en) 2018-11-19
GEP20207129B (en) 2020-07-10
HRP20181715T1 (hr) 2019-04-05
EP3141252A1 (en) 2017-03-15
JP6620135B2 (ja) 2019-12-11
CN102458408B (zh) 2015-06-03
CN110540538A (zh) 2019-12-06
EA201500871A8 (ru) 2019-02-28
TR201815272T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
ES2692396T3 (es) Inhibidores de la replicación de virus de influenza
AU2020264300B2 (en) HIV Inhibitor Compounds
ES2763535T3 (es) Inhibidores de la replicación de virus de la gripe
JP6411491B2 (ja) 多環式カルバモイルピリドン化合物およびhiv感染症を処置するためのその使用
JP6411492B2 (ja) 多環式カルバモイルピリドン化合物およびhiv感染症を処置するためのその使用
TWI858267B (zh) 用於治療hiv之蛋白殼抑制劑
AU2003214503B2 (en) Tropane derivatives as CCR5 modulators
CN102906091B (zh) 苦参酸/碱衍生物及其制备方法和用途
EP3191489B1 (en) Pyrrolopyrimidines for use in influenza virus infection
ES2623777T3 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CN111410661B (zh) 帽依赖性内切核酸酶抑制剂及其用途
EA026140B1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
AU2020401999B2 (en) Compound as cyclin-dependent kinase 9 inhibitor and use thereof
AU2015342883A1 (en) Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
ES2957767T3 (es) Triterpenoides modificados en C-3 y C-17 como inhibidores del VIH-1
BR112016023414B1 (pt) Composto, composição farmacêutica, e, uso do composto
JP2024178221A (ja) Pd-l1拮抗薬化合物
JP2019522059A (ja) S1p1アゴニスト及びその応用
AU2018200219B2 (en) Inhibitors of Influenza Viruses Replication
TWI908223B (zh) Hiv抑制劑化合物
AU2015203600B2 (en) Inhibitors of Influenza Viruses Replication
HK40080472A (en) Hiv inhibitor compounds
BR122023025728A2 (pt) Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7hpirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus, seus usos para tratamento de influenza, composição farmacêutica, e combinação
HK40018376A (en) Hiv inhibitor compounds
BR102018002152B1 (pt) Compostos, composições farmacêuticas e seus usos como inibidores de hiv